Eden Biodesign Ltd, an innovative provider of development and manufacturing services for new medicines, announced today that it has been selected by ImmBio (Cambridge, UK), a leading biotechnology company developing the next generation of anti-infective vaccines, to provide a range of development and manufacturing services for their leading influenza vaccine programme. This targets both seasonal and pandemic flu, where manufacturing speed and flexibility is critical to meet unmet market needs.
Graham Clarke, CEO of ImmBio said: "Working with Eden Biodesign will allow us to rapidly advance the next generation influenza vaccine forward towards a Clinical Trial Application and is consistent with our aggressive timelines for bringing our viral lead product to the clinic. We are delighted for the development of our leading influenza programme to be managed by Eden Biodesign at their state of the art facility in Liverpool."
Dr Crawford Brown, CEO of Eden Biodesign commented: "We are very pleased to work with ImmBio on the further development of this promising vaccine and to accelerate its progress from research to the clinic. Eden Biodesign has the expertise in product development and manufacturing that is critical to ensure clinical and commercial success of this product."
Eden Biodesign is the operator of the National Biomanufacturing Centre (NBC) facility, part of the £34.25 million NBC project developed and owned by the NWDA and funded by the NWDA, ERDF[ii] and DTI[iii].
Northwest Regional Development Agency (NWDA)
[ii] European Regional Development Fund (ERDF)
[iii] Department of Trade and Industry (DTI)